6-K filed Aug 12, 2026 at 06:51 ET
Pharvaris reported Q2 2026 financial results with no revenue, a net loss of €47.8M (€0.70/share), and cash of €318M. The key catalyst is the expected topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026, alongside the ongoing FDA review of the deucrictibant IR NDA with a PDUFA date of April 23, 2027. The May 2026 $132M offering extends the cash runway into 2028, funding pre-commercial activities and lifecycle management, but the pre-revenue stage and increasing operating losses keep the stock binary on pipeline execution.